Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Teva
McKesson
Farmers Insurance
Chinese Patent Office
Cipla
Boehringer Ingelheim
Deloitte

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,353,088

« Back to Dashboard

Which drugs does patent 9,353,088 protect, and when does it expire?

Patent 9,353,088 protects XIIDRA and is included in one NDA.

This patent has one patent family member in one country.
Summary for Patent: 9,353,088
Title:Crystalline pharmaceutical and methods of preparation and use thereof
Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##
Inventor(s): Burnier; John (Pacifica, CA)
Assignee: SARcode Bioscience Inc. (Brisbane, CA)
Application Number:14/556,715
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,353,088

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,353,088

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,890,141 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Sign Up
8,378,105 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Sign Up
8,927,574 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Cerilliant
Cipla
Chinese Patent Office
Chubb
Moodys
Fish and Richardson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.